The South Korean market has experienced a modest uptick, rising 1.1% over the last week and 4.9% over the past year, with earnings projected to grow by 30% annually. In this favorable environment, companies with high insider ownership and strong earnings growth potential are particularly appealing as they often indicate confidence from those closest to the business in its future prospects.
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.4% | 35.6% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.8% | 49.1% |
Bioneer (KOSDAQ:A064550) | 15.8% | 97.6% |
Oscotec (KOSDAQ:A039200) | 26.1% | 122% |
ALTEOGEN (KOSDAQ:A196170) | 26.6% | 99.5% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 105.8% |
Vuno (KOSDAQ:A338220) | 19.4% | 110.9% |
UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
Techwing (KOSDAQ:A089030) | 18.7% | 83.6% |
INTEKPLUS (KOSDAQ:A064290) | 16.3% | 96.7% |
Let's dive into some prime choices out of the screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: Techwing, Inc. develops, manufactures, sells, and services semiconductor inspection equipment in South Korea and internationally with a market cap of ₩1.34 trillion.
Operations: Techwing's revenue is primarily derived from its semiconductor inspection equipment business, which operates both domestically in South Korea and internationally.
Insider Ownership: 18.7%
Earnings Growth Forecast: 83.6% p.a.
Techwing is experiencing significant revenue growth, with a forecasted annual increase of 62.5%, outpacing the South Korean market's average. Despite recent net losses, analysts expect profitability within three years, driven by an anticipated 83.65% annual earnings growth and a projected high return on equity of 50%. However, financial stability remains a concern as interest payments are not well covered by earnings and share price volatility persists without substantial insider trading activity recently.
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩20.53 trillion.
Operations: The company generates revenue of ₩90.79 million from its biotechnology segment.
Insider Ownership: 26.6%
Earnings Growth Forecast: 99.5% p.a.
ALTEOGEN is poised for substantial growth, with revenue expected to rise by 64.2% annually, significantly outpacing the South Korean market average. Analysts forecast profitability within three years, driven by an impressive projected earnings growth of 99.46% per year and a very high return on equity of 66.3%. Despite past shareholder dilution, the stock trades at a significant discount to its estimated fair value, offering potential upside as it transitions towards profitability.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Doosan Corporation operates in heavy industry, machinery manufacturing, and apartment construction across South Korea and globally, with a market cap of ₩2.93 trillion.
Operations: The company's revenue is primarily derived from Doosan Bobcat with ₩9.31 billion, followed by Doosan Energy at ₩8.25 billion, Electronic BG at ₩855.42 million, Doosan Fuel Cell at ₩279.99 million, and Digital Innovation BU contributing ₩286.29 million.
Insider Ownership: 38.9%
Earnings Growth Forecast: 65.5% p.a.
Doosan's growth prospects are tempered by a forecasted revenue increase of 3.7% annually, which lags behind the South Korean market average. However, analysts expect it to achieve profitability within three years with earnings projected to grow at 65.51% per year and a high return on equity of 20%. The stock trades significantly below its estimated fair value and was recently added to the S&P Global BMI Index, indicating potential recognition in global markets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com